Valued at USD 1.18 Billion in 2025, the drug coated balloon catheter market is projected to reach USD 1.27 Billion in 2026 and USD 2.41 Billion by 2034, growing at a CAGR of 8.28% during the forecast period 2026–2034. Notable players include Boston Scientific Corporation, Medtronic plc, B. Braun SE, Concept Medical Inc., Abbott, Koninklijke Philips N.V., Teleflex Incorporated, MicroPort Scientific Corporation, iVascular S.L.U., Meril Life Sciences Pvt. Ltd., Cordis, and Translumina Therapeutics. This article examines care settings, device innovation and the commercial barriers that decision-makers should monitor.

Minimally Invasive Procedures Drive Adoption

Growing preference for minimally invasive procedures is raising the use of angioplasty across hospitals and cardiac care centers. According to the National Library of Medicine, minimally invasive cardiac surgery accounts for one-third of total heart surgeries globally, including mitral valve repair, aortic valve replacement and coronary artery bypass. These approaches are associated with lower complication risks and shorter recovery periods, and demand is rising as providers focus on minimizing repeat procedures and achieving higher success rates with vascular treatments.

Hospitals dominated the end-use landscape in 2025, owing to the high volume of cardiovascular and vascular intervention procedures performed there and the availability of advanced imaging technology, medical practitioners and healthcare facilities.

Specialty Cardiac Centers and Ambulatory Surgical Centers

Specialty cardiac centers are projected to grow at the fastest end-use CAGR during the forecast period, owing to increasing preference for specialized cardiovascular treatment facilities. Rising focus on advanced interventional cardiology, shorter patient recovery times and improved outcomes supports expansion. Ambulatory surgical centers complete the end-use picture alongside hospitals and specialty cardiac centers, according to the report.

In Latin America and the Middle East & Africa, growth in specialty cardiac centers, expansion of private healthcare providers and access to catheter-based treatments are supporting adoption in countries such as Brazil, Mexico, South Africa and the UAE.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/drug-coated-ballon-catheter-market

Balloon Coating Technologies and Product Innovation

Continuous evolution is improving how devices deliver drugs. Innovations in balloon coating technologies, catheter flexibility and drug-transfer mechanisms are reducing restenosis risks and expanding applications. Technological advances in paclitaxel-coated balloons are also supporting the coronary segment.

Recent developments show the pace of change. In February 2025, MicroPort's Firelimus drug-eluting balloon catheter received market approval from China's National Medical Products Administration, designed for rapid drug transfer to the vessel wall with sustained, controlled release. The same month, BrosMed partnered with Cordis to distribute its VaSecure drug-coated balloon catheter in China. Boston Scientific has also launched AGENT, designed to provide efficient drug delivery in complex anatomy.

Reimbursement Policies, Cost Barriers and Emerging Markets

High device cost is the main restraint. Drug-coated balloon catheters involve costly devices, catheterization equipment and interventional skills, which limits use among budget-conscious providers and in developing nations. Gaps in reimbursement policies and expensive procedures add further barriers, so reimbursement policies and procedure cost remain central to purchasing decisions in developing markets.

Emerging markets offer a counterweight. Asia Pacific is projected to grow at the fastest regional CAGR, and the Indian Government allocated USD 11.50 billion in its Union budget 2025–2026, up 9.78% from FY25, for developing and maintaining the healthcare sector. Rising government healthcare investment and expansion of cardiac care centers further support regional growth, and improving infrastructure and growing awareness of minimally invasive treatment are expected to support demand.

Competitive Landscape and Investment Outlook

The Drug Coated Balloon Catheter market is moderately fragmented, with manufacturers competing on product performance, technology and pricing. Polaris benchmarking describes Boston Scientific as a global leader pursuing innovation-driven development, Medtronic as broad in portfolio with high R&D capability, and B. Braun as strong in Europe through partnerships. Investment activity is directed toward advanced drug delivery systems, superior balloon coatings and catheter technology designed to minimize restenosis. Players are focusing on advanced drug-delivery technologies and on expanding minimally invasive treatment solutions to strengthen market presence. The outlook remains strong on emerging-market expansion and technological advancement.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market